Better analysis for better decisions: Has pharmacoeconomics come of age?

PharmacoEconomics

Volumn 24, Issue 2, 2006, Pages 107-108

  Drummond, Michael ^a   Sculpher, Mark ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AUSTRALIA; CANADA; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; EDITORIAL; HEALTH; MEDICINE; PRIORITY JOURNAL; REIMBURSEMENT; STATISTICAL ANALYSIS; UNITED KINGDOM; WORK;

DECISION SUPPORT TECHNIQUES; ECONOMICS, PHARMACEUTICAL; HUMANS;

EID: 32644451621     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200624020-00001     Document Type: Editorial

References (12)

1. Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions: so much for guidelines. Pharmacoeconomics 2000; 18 (1): 55-62
2. Hill SR, Mitchell AS, Henry D. Problems with the interpretation of pharmacoeconomic analyses: a review of submission to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283 (16): 2116-21
3. Weinstein MC, Toy EL, Samberg EA, et al. Modeling for health care and other policy decisions: uses, roles and validity. Value Health 2001; 4: 348-61
4. Phillips Z, Ginnelly L, Sculpher M, et al. A review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36): 1-158
5. Nord E, Pinto JL, Richardson J, et al. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ 1999; 8: 25-39
6. Williams AH. Intergenerational equity: an exploration of the 'fair innings' argument. Health Econ 1997; 6: 117-32
7. Manca A, Rice N, Sculpher MJ, et al. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 2005; 14: 471-85
8. Grieve R, Nixon R, Thompson S, et al. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ 2005; 14: 185-96
9. Willan AR, Pinto EM, O'Brien BJ, et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Econ 2005; 14: 327-38
10. Barbieri M, Drummond MF, Wilke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005; 8: 10-23
11. Ades AE, Sculpher MJ, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24 (1): 1-19
12. Sculpher MJ, Claxton KP. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty: when is there sufficient evidence? Value Health 2005; 8: 433-46